Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Star Bulk Announces Dates for the Release of Fourth Quarter and Twelve Months Ended December .
Star Bulk Carriers Corp.February 8, 2021 GMT
ATHENS, Greece, Feb. 08, 2021 (GLOBE NEWSWIRE) Star Bulk Carriers Corp. (the “Company” or “Star Bulk”) (Nasdaq: SBLK), today announced that it will release its results for the fourth quarter and twelve months ended December 31, 2020 after the market closes in New York on Wednesday, February 17, 2021. Star Bulk’s management team will host a conference call to discuss the Company’s financial results on Thursday, February 18, 2021 at 11:00 a.m. Eastern Time (ET).
10 Best High Yield Stocks To Buy Now
In this article we discuss 10 best high yield stocks to buy now. You can skip our discussion of why do we think it’s a good strategy to invest in dividend stocks in 2021 and go directly to 5 Best High Yield Stocks to Buy Now.
Is Dividend Investing a Good Strategy in 2021?
There is a lot of debate around the merits and long-term viability of dividend investing. The crux of this debate is this: a dividend is not free money. In reality it is a transfer of money from a company to you. That comes at a cost. For example, let’s say a company is worth $1000 with 100 shares ($10 per share). Say this company is paying a dividend of $1 per share. When this dividend is paid, the company’s worth actually declines by $100 ($1/share 100 shares). So the total value of the company is now $900. Dividend investing is based on a trade-off. Instead of putting money into long-term growth projects that will drive its stock price higher and increase returns, a
DURHAM - Life sciences firm Bioventus is gearing up to launch its IPO this week, looking to raise as much as $125 million. The stock was priced at between $16
Two Rare Disease Biotechs Hit the Market in Upsized IPOs globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.
Immunocore Announces Pricing of Upsized Initial Public Offering
PRESS RELEASE
Immunocore Announces Pricing of Upsized Initial Public Offering
OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US – 4 February 2021 – Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced the pricing of its upsized initial public offering in the United States of 9,935,896 American Depositary Shares (“ADSs”) representing 9,935,896 ordinary shares at an initial public offering price of $26.00 per ADS, for total gross proceeds of approximately $258.3 million. All ADSs sold in the offering were offered by Immunocore. The ADSs are expected to begin trading on The Nasdaq Global Select Market on February 5, 2021 under the ticker symbol “IMCR.” In addition, I